USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 2, 2022 | Sep 2022 | $-0.30 | - | $-0.31 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 2, 2022 | Sep 2022 | $540.00K | - | $1.40M |
Aeglea Biotherapeutics's next earnings date is Wednesday, Nov 2, 2022 for the fiscal quarter ending Sep 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Sep 2022 | 6 | $-0.30 | $-0.35 | $-0.24 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 8 | $-1.28 | $-1.44 | $-1.11 |
| Dec 2023 | 7 | $-1.00 | $-1.37 | $-0.57 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Sep 2022 | 0 / 0 | $-0.30 | $-0.30 | $-0.35 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-1.28 | $-1.27 | $-1.37 |
| Dec 2023 | 0 / 0 | $-1.00 | $-1.02 | $-1.16 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Sep 2022 | 5 | $540.00K | $0.00 | $1.50M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 5 | $2.93M | $1.00M | $5.86M |
| Dec 2023 | 5 | $21.72M | $10.00M | $48.70M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | $-0.31 | - | - |
| May 5, 2022 | Mar 2022 | $-0.34 | $-0.37 | -8.82% |
| Mar 8, 2022 | Dec 2021 | $-0.29 | $-0.31 | -6.90% |
| Nov 4, 2021 | Sep 2021 | $-0.28 | $-0.31 | -10.71% |
| Aug 5, 2021 | Jun 2021 | $-0.16 | $-0.10 | 37.50% |
| May 10, 2021 | Mar 2021 | $-0.17 | $-0.28 | -64.71% |
| Mar 18, 2021 | Dec 2020 | $-0.31 | $-0.35 | -12.90% |
| Nov 5, 2020 | Sep 2020 | $-0.39 | $-0.29 | 25.64% |
| Aug 10, 2020 | Jun 2020 | $-0.44 | $-0.40 | 9.09% |
| May 7, 2020 | Mar 2020 | $-0.65 | $-0.57 | 12.31% |
| Feb 24, 2020 | Dec 2019 | $-0.68 | $-0.65 | 4.41% |
| Nov 6, 2019 | Sep 2019 | $-0.54 | $-0.66 | -22.22% |
| Aug 6, 2019 | Jun 2019 | $-0.49 | $-0.55 | -12.24% |
| May 7, 2019 | Mar 2019 | $-0.56 | $-0.59 | -5.36% |
| Mar 7, 2019 | Dec 2018 | $-0.37 | $-0.62 | -67.57% |
| Nov 8, 2018 | Sep 2018 | $-0.45 | $-0.54 | -20.00% |
| Aug 9, 2018 | Jun 2018 | $-0.38 | $-0.46 | -21.05% |
| May 8, 2018 | Mar 2018 | $-0.44 | $-0.49 | -11.36% |
| Mar 13, 2018 | Dec 2017 | $-0.53 | $-0.38 | 28.30% |
| Nov 7, 2017 | Sep 2017 | $-0.55 | $-0.48 | 12.73% |
| Aug 9, 2017 | Jun 2017 | $-0.48 | $-0.47 | 2.08% |
| May 9, 2017 | Mar 2017 | $-0.47 | $-0.47 | - |
| Mar 23, 2017 | Dec 2016 | $-0.45 | $-0.56 | -24.44% |
| Nov 9, 2016 | Sep 2016 | $-0.55 | $-0.47 | 14.55% |
| Aug 9, 2016 | Jun 2016 | $-0.42 | $-0.46 | -9.52% |
| Apr 12, 2016 | Mar 2016 | $-0.47 | $-7.10 | -1410.64% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 8, 2022 | Dec 2021 | $-1.00 | $-1.00 | - |
| Mar 18, 2021 | Dec 2020 | $-1.50 | $-1.61 | - |
| Feb 24, 2020 | Dec 2019 | $-2.48 | $-2.45 | - |
| Mar 7, 2019 | Dec 2018 | $-1.84 | $-2.11 | - |
| Mar 13, 2018 | Dec 2017 | $-1.95 | $-1.80 | - |
| Mar 23, 2017 | Dec 2016 | - | $-8.59 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | $570.00K | - | - |
| May 5, 2022 | Mar 2022 | $1.32M | $1.36M | 1.03% |
| Mar 8, 2022 | Dec 2021 | $3.07M | $-11.45M | - |
| Nov 4, 2021 | Sep 2021 | $4.05M | $1.40M | 0.35% |
| Aug 5, 2021 | Jun 2021 | $12.15M | $13.70M | 1.13% |
| May 10, 2021 | Mar 2021 | $13.00M | $0.00 | - |
| Mar 18, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Nov 5, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 10, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 7, 2020 | Mar 2020 | $3.36M | $0.00 | - |
| Feb 24, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 6, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 6, 2019 | Jun 2019 | $300.00K | $0.00 | - |
| May 7, 2019 | Mar 2019 | $300.00K | $0.00 | - |
| Mar 7, 2019 | Dec 2018 | $1.98M | $3.89M | 1.96% |
| Nov 8, 2018 | Sep 2018 | $1.16M | $2.38M | 2.05% |
| Aug 9, 2018 | Jun 2018 | $1.63M | $2.38M | 1.46% |
| May 8, 2018 | Mar 2018 | $1.07M | $1.51M | 1.41% |
| Mar 13, 2018 | Dec 2017 | $1.16M | $1.48M | 1.28% |
| Nov 7, 2017 | Sep 2017 | - | $1.26M | - |
| Aug 9, 2017 | Jun 2017 | - | $1.48M | - |
| May 9, 2017 | Mar 2017 | - | $982.00K | - |
| Mar 23, 2017 | Dec 2016 | - | $1.25M | - |
| Nov 9, 2016 | Sep 2016 | - | $1.15M | - |
| Aug 9, 2016 | Jun 2016 | - | $1.37M | - |
| Apr 12, 2016 | Mar 2016 | - | $859.00K | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 8, 2022 | Dec 2021 | $18.30M | $18.74M | 2.40% |
| Mar 18, 2021 | Dec 2020 | $0.00 | $21.84K | - |
| Feb 24, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Mar 7, 2019 | Dec 2018 | $4.49M | $3.89M | -13.41% |
| Mar 13, 2018 | Dec 2017 | $4.88M | $5.21M | 6.66% |
| Mar 23, 2017 | Dec 2016 | - | $4.63M | - |
AGLE's next earnings date is Wednesday, Nov 2, 2022 for the fiscal quarter ending Sep 30, 2022.
According to analysts, the average EPS estimation for Aeglea Biotherapeutics's next quarterly earnings is $-0.30, with a low EPS estimation of $-0.35, and a high estimation of $-0.24.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.30, the last 2 month trend is $-0.30, and the 3 month trend is $-0.35.
Based on analysts, the average revenue estimation is $540.00K, with a low revenue estimation of $0.00, and a high estimation of $1.50M.
Aeglea Biotherapeutics's previous earnings date was Aug 3, 2022 for its fiscal quarter ended Jun 30, 2022.
Aeglea Biotherapeutics's previous annual earnings date was Mar 8, 2022 for its fiscal year ended Dec 31, 2021.
AGLE's earnings per share (EPS) was $-1.00, beating the consensus analysts forecast of $-1.00 by 0.00% , and higher than the previous year's EPS (Dec 2020) by -37.89%.
Revenues were $18.74M, better than the forecast of $18.30M by 2.40%, and up by 85689.50% from previous year's revenue.
The company reported a net income of $-65.80M.
Aeglea Biotherapeutics reported a free cash flow of $-54.29M for its fiscal year, compared to $-80.06M a year ago.
The company ended the fiscal year with $9.65M in total debt, an increase of 77.17% compared to the previous year.
